(ANAV) AXA IM NASDAQ 100 - USD - Ratings and Ratios

Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: IE000QDFFK00

fund Shares, Large-Cap Growth, US Stocks, Diversification, Tracking Index

Description: ANAV AXA IM NASDAQ 100 - USD

The AXA IM NASDAQ100 UCITS ETF - USD Acc EUR is an exchange-traded fund listed on XETRA under the ticker symbol ANAV. It is designed to track the Morningstar US LM Brd Growth NR USD Index, providing investors with exposure to US large-cap growth equities. As a UCITS-compliant ETF, it adheres to the Undertakings for the Collective Investment in Transferable Securities directive, making it accessible to a broad range of investors across Europe.

From a technical analysis perspective, the ETFs price is currently below its 20-day Simple Moving Average (SMA20) of $18.55, indicating a short-term downtrend. The 50-day SMA ($16.91) and 200-day SMA ($16.75) are closely aligned, suggesting a stable long-term trend. The Average True Range (ATR) of 0.30 represents a daily price volatility of 1.85%, which is relatively moderate. The ETFs price is also below its 52-week high of $19.06 and above its 52-week low of $13.49, indicating that it is currently in a consolidation phase.

Fundamentally, the AXA IM NASDAQ100 UCITS ETF has a substantial Assets Under Management (AUM) of €1.056 billion, indicating a strong investor base and liquidity. The funds focus on US large-cap growth equities positions it to benefit from the long-term growth prospects of the US technology and growth sectors, which are heavily represented in the NASDAQ-100 Index.

Forecasting the ETFs future performance involves analyzing both technical and fundamental data. Given the current technical downtrend and the ETFs position relative to its SMAs, a potential short-term target could be the 52-week low of $13.49 if the downtrend continues. However, if the ETF can break above the SMA20, it may signal a reversal and potential upward movement towards the 52-week high of $19.06. Fundamentally, the strong AUM and the ETFs exposure to US large-cap growth equities provide a solid foundation for long-term growth. Therefore, a forecast of moderate short-term volatility followed by potential long-term growth is plausible, assuming the US large-cap growth sector continues to perform well.

Additional Sources for ANAV ETF

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

ANAV ETF Overview

Market Cap in USD 1,247m
Category US Large-Cap Growth Equity
IPO / Inception 2022-11-16

ANAV ETF Ratings

Growth Rating 60.7
Fundamental -
Dividend Rating 0.0
Rel. Strength -8.5
Analysts -
Fair Price Momentum 15.47 EUR
Fair Price DCF -

ANAV Dividends

Currently no dividends paid

ANAV Growth Ratios

Growth Correlation 3m 90.8%
Growth Correlation 12m 56%
Growth Correlation 5y 94%
CAGR 5y 21.71%
CAGR/Max DD 5y 0.81
Sharpe Ratio 12m 0.45
Alpha -11.78
Beta 1.007
Volatility 17.13%
Current Volume 105.6k
Average Volume 20d 16.4k
What is the price of ANAV shares?
As of July 03, 2025, the stock is trading at EUR 16.64 with a total of 105,635 shares traded.
Over the past week, the price has changed by -13.64%, over one month by -9.95%, over three months by +6.93% and over the past year by +4.08%.
Is AXA IM NASDAQ 100 - USD a good stock to buy?
Yes. Based on ValueRay's Analyses, AXA IM NASDAQ 100 - USD (XETRA:ANAV) is currently (July 2025) a good stock to buy. It has a ValueRay Growth Rating of 60.66 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANAV is around 15.47 EUR . This means that ANAV is currently overvalued and has a potential downside of -7.03%.
Is ANAV a buy, sell or hold?
AXA IM NASDAQ 100 - USD has no consensus analysts rating.
What are the forecasts for ANAV share price target?
According to our own proprietary Forecast Model, ANAV AXA IM NASDAQ 100 - USD will be worth about 18.2 in July 2026. The stock is currently trading at 16.64. This means that the stock has a potential upside of +9.07%.
Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 18.2 9.1%